<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00308113</url>
  </required_header>
  <id_info>
    <org_study_id>PITT0503</org_study_id>
    <nct_id>NCT00308113</nct_id>
  </id_info>
  <brief_title>CoQ10 and Prednisone in Non-Ambulatory DMD</brief_title>
  <official_title>PITT0503: Clinical Trial of Coenzyme Q10 and Prednisone in Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cooperative International Neuromuscular Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Cooperative International Neuromuscular Research Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will help determine if CoQ10 and prednisone, alone and as a combination decrease
      the decline in cardiopulmonary and skeletal muscle function that occurs in the wheelchair
      confined phase of DMD. Participants who are enrolled in this study should not have taken any
      corticosteroids within the last six months. This is a 13-month, prospective, randomized study
      comparing a daily prednisone arm (0.75mg/kg/day), a CoQ10 arm (serum of greater than 2.5
      ug/mL) and a combination arm (prednisone and CoQ10) with an enhanced standard of care arm in
      wheelchair confined males age 10 to 18 years with an established DMD diagnosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Duchenne muscular dystrophy (DMD) is the most common form of muscular dystrophy affecting
      1:3500 male births worldwide. Despite an increase in our understanding of the disorder since
      the discovery and characterization of the causative gene and its product dystrophin in 1987,
      current therapeutic management remains largely supportive. Improvement in the treatment of
      DMD will depend upon the development of better therapies. Affected boys become symptomatic at
      3 to 5 years of age with proximal leg weakness that impairs mobility, ability to get up from
      a squat, and precludes a normal ability to run. By 8 years of age, some affected boys begin
      to lose the ability to walk and resort to a wheelchair for mobility. This shift from the
      ambulant to non-ambulant phase occurs in all boys with a diagnosis of DMD by age 12 years. In
      this study, participants will be randomized into groups after being screened to determine
      eligibility. Participants will then be followed for a 12-month investigation period.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    New enrollment has been suspended, currently following previously enrolled participants
  </why_stopped>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>One Year Change of Left Ventricular Mean Systolic Wall Stress/Rate-corrected Velocity of Fiber Shortening Relation.</measure>
    <time_frame>12 months</time_frame>
    <description>Comparing change from baseline of mean systolic wall stress and rate-corrected mean velocity of circumferential shortening in the three treatment groups relative to the enhanced standard of care group and relative to each other at one year. The values are obtained via an echocardiogram read locally at each site.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>One Year Change in Pulmonary Function (Forced Expiratory Volume, FEV1 and Forced Vital Capacity, FVC)</measure>
    <time_frame>12 months</time_frame>
    <description>Comparing change from baseline levels in pulmonary function (FEV1 and FVC) in the three treatment groups relative to the enhanced standard of care group and relative to each other at one year.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare Side Effect Profiles of the Three Study Groups</measure>
    <time_frame>12 months</time_frame>
    <description>To compare side effect profiles of the three regimens to the enhanced standard of care group, to include height, weight, weight/height ratio, body mass index, cataract formation, blood glucose, blood pressure, and behavioral changes.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CoenzymeQ10 taken once a day each morning by mouth.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prednisone taken once a day each morning by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CoenzymeQ10 and prednisone each taken once a day in the morning by mouth.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Enhanced standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone 0/75 mg/kg/day.</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Coenzyme Q10</intervention_name>
    <description>serum levels of greater or equal to 2.5 micrograms/mL.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>CoQ10</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 10-18 years

          -  Non-ambulatory (primary mode of transportation is via wheelchair for 3 years or less)

          -  Confirmed DMD diagnosis

          -  Steroid-naive for the 6 months prior to screening

          -  Stable dose of b-blocker or ACE inhibitor medication for the 6 months prior to
             screening, if taking either of these medications

          -  Ability to provide reproducible repeat QMT grip score within 15% of first assessment
             score

          -  Has not participated in other therapeutic research protocol within the last 6 months
             prior to screening

          -  Ability to swallow tablets

        Exclusion Criteria:

          -  Failure to achieve one or more of the diagnostic inclusion criteria cited above

          -  Symptomatic DMD carrier

          -  Use of carnitine, other amino acids, creatine, glutamine, CoQ10 or any herbal
             medicines (this would not include herbal teas unless they are consumed daily with
             intended medicinal effect) within the last 3 months

          -  History of significant concomitant illness or significant impairment of renal or
             hepatic function, or other contraindication to steroid therapy

          -  Positive PPD

          -  No prior exposure to chickenpox and no immunization against chicken pox

          -  Baseline serum CoQ10 level of 5.0mg/ml or greater
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paula R Clemens, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Puerto Rico</country>
  </removed_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2006</study_first_submitted>
  <study_first_submitted_qc>March 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2006</study_first_posted>
  <results_first_submitted>August 7, 2013</results_first_submitted>
  <results_first_submitted_qc>August 7, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 11, 2013</results_first_posted>
  <last_update_submitted>October 16, 2013</last_update_submitted>
  <last_update_submitted_qc>October 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Muscular dystrophy</keyword>
  <keyword>Duchenne</keyword>
  <keyword>CoQ10</keyword>
  <keyword>prednisone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Coenzyme Q10</mesh_term>
    <mesh_term>Ubiquinone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment started in April 2007 at two participating centers of the Cooperative International Neuromuscular Research Group (CINRG): University of Pittsburgh and University of Puerto Rico. Enrollment closed in December 2008 by the CINRG Data and Safety Monitoring Board (DSMB) due to changes in standard of care.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Coenzyme Q10 Alone</title>
          <description>CoenzymeQ10 taken once a day each morning by mouth.
Coenzyme Q10 : serum levels of greater or equal to 2.5 micrograms/mL.</description>
        </group>
        <group group_id="P2">
          <title>Prednisone Alone</title>
          <description>Prednisone taken once a day each morning by mouth
Prednisone : Prednisone 0/75 mg/kg/day.</description>
        </group>
        <group group_id="P3">
          <title>Coenzyme Q10 and Prednisone</title>
          <description>CoenzymeQ10 and prednisone each taken once a day in the morning by mouth.
Coenzyme Q10 : serum levels of greater or equal to 2.5 micrograms/mL.
Prednisone : Prednisone 0/75 mg/kg/day.</description>
        </group>
        <group group_id="P4">
          <title>Enhanced Standard of Care</title>
          <description>Enhanced standard of care.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol closure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Coenzyme Q10 Alone</title>
          <description>CoenzymeQ10 taken once a day each morning by mouth.
Coenzyme Q10 : serum levels of greater or equal to 2.5 micrograms/mL.</description>
        </group>
        <group group_id="B2">
          <title>Prednisone Alone</title>
          <description>Prednisone taken once a day each morning by mouth
Prednisone : Prednisone 0/75 mg/kg/day.</description>
        </group>
        <group group_id="B3">
          <title>Coenzyme Q10 and Prednisone</title>
          <description>CoenzymeQ10 and prednisone each taken once a day in the morning by mouth.
Coenzyme Q10 : serum levels of greater or equal to 2.5 micrograms/mL.
Prednisone : Prednisone 0/75 mg/kg/day.</description>
        </group>
        <group group_id="B4">
          <title>Enhanced Standard of Care</title>
          <description>Enhanced standard of care.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="1"/>
            <count group_id="B4" value="2"/>
            <count group_id="B5" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>10-18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>One Year Change of Left Ventricular Mean Systolic Wall Stress/Rate-corrected Velocity of Fiber Shortening Relation.</title>
        <description>Comparing change from baseline of mean systolic wall stress and rate-corrected mean velocity of circumferential shortening in the three treatment groups relative to the enhanced standard of care group and relative to each other at one year. The values are obtained via an echocardiogram read locally at each site.</description>
        <time_frame>12 months</time_frame>
        <population>No analysis was performed as only 1 out of 3 participants completed all echocardiogram measurements before the protocol was closed.</population>
        <group_list>
          <group group_id="O1">
            <title>Coenzyme Q10 Alone</title>
            <description>CoenzymeQ10 taken once a day each morning by mouth.
Coenzyme Q10 : serum levels of greater or equal to 2.5 micrograms/mL.</description>
          </group>
          <group group_id="O2">
            <title>Prednisone Alone</title>
            <description>Prednisone taken once a day each morning by mouth
Prednisone : Prednisone 0/75 mg/kg/day.</description>
          </group>
          <group group_id="O3">
            <title>Coenzyme Q10 and Prednisone</title>
            <description>CoenzymeQ10 and prednisone each taken once a day in the morning by mouth.
Coenzyme Q10 : serum levels of greater or equal to 2.5 micrograms/mL.
Prednisone : Prednisone 0/75 mg/kg/day.</description>
          </group>
          <group group_id="O4">
            <title>Enhanced Standard of Care</title>
            <description>Enhanced standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>One Year Change of Left Ventricular Mean Systolic Wall Stress/Rate-corrected Velocity of Fiber Shortening Relation.</title>
          <description>Comparing change from baseline of mean systolic wall stress and rate-corrected mean velocity of circumferential shortening in the three treatment groups relative to the enhanced standard of care group and relative to each other at one year. The values are obtained via an echocardiogram read locally at each site.</description>
          <population>No analysis was performed as only 1 out of 3 participants completed all echocardiogram measurements before the protocol was closed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>One Year Change in Pulmonary Function (Forced Expiratory Volume, FEV1 and Forced Vital Capacity, FVC)</title>
        <description>Comparing change from baseline levels in pulmonary function (FEV1 and FVC) in the three treatment groups relative to the enhanced standard of care group and relative to each other at one year.</description>
        <time_frame>12 months</time_frame>
        <population>No analysis was performed as only 1 out of 3 participants completed all the pulmonary function measurements before the protocol was closed.</population>
        <group_list>
          <group group_id="O1">
            <title>Coenzyme Q10 Alone</title>
            <description>CoenzymeQ10 taken once a day each morning by mouth.
Coenzyme Q10 : serum levels of greater or equal to 2.5 micrograms/mL.</description>
          </group>
          <group group_id="O2">
            <title>Prednisone Alone</title>
            <description>Prednisone taken once a day each morning by mouth
Prednisone : Prednisone 0/75 mg/kg/day.</description>
          </group>
          <group group_id="O3">
            <title>Coenzyme Q10 and Prednisone</title>
            <description>CoenzymeQ10 and prednisone each taken once a day in the morning by mouth.
Coenzyme Q10 : serum levels of greater or equal to 2.5 micrograms/mL.
Prednisone : Prednisone 0/75 mg/kg/day.</description>
          </group>
          <group group_id="O4">
            <title>Enhanced Standard of Care</title>
            <description>Enhanced standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>One Year Change in Pulmonary Function (Forced Expiratory Volume, FEV1 and Forced Vital Capacity, FVC)</title>
          <description>Comparing change from baseline levels in pulmonary function (FEV1 and FVC) in the three treatment groups relative to the enhanced standard of care group and relative to each other at one year.</description>
          <population>No analysis was performed as only 1 out of 3 participants completed all the pulmonary function measurements before the protocol was closed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compare Side Effect Profiles of the Three Study Groups</title>
        <description>To compare side effect profiles of the three regimens to the enhanced standard of care group, to include height, weight, weight/height ratio, body mass index, cataract formation, blood glucose, blood pressure, and behavioral changes.</description>
        <time_frame>12 months</time_frame>
        <population>No analysis was performed as the study was closed with N=3 out of 120 and side effects profile between groups could not be analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Coenzyme Q10 Alone</title>
            <description>CoenzymeQ10 taken once a day each morning by mouth.
Coenzyme Q10 : serum levels of greater or equal to 2.5 micrograms/mL.</description>
          </group>
          <group group_id="O2">
            <title>Prednisone Alone</title>
            <description>Prednisone taken once a day each morning by mouth
Prednisone : Prednisone 0/75 mg/kg/day.</description>
          </group>
          <group group_id="O3">
            <title>Coenzyme Q10 and Prednisone</title>
            <description>CoenzymeQ10 and prednisone each taken once a day in the morning by mouth.
Coenzyme Q10 : serum levels of greater or equal to 2.5 micrograms/mL.
Prednisone : Prednisone 0/75 mg/kg/day.</description>
          </group>
          <group group_id="O4">
            <title>Enhanced Standard of Care</title>
            <description>Enhanced standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Compare Side Effect Profiles of the Three Study Groups</title>
          <description>To compare side effect profiles of the three regimens to the enhanced standard of care group, to include height, weight, weight/height ratio, body mass index, cataract formation, blood glucose, blood pressure, and behavioral changes.</description>
          <population>No analysis was performed as the study was closed with N=3 out of 120 and side effects profile between groups could not be analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Coenzyme Q10 Alone</title>
          <description>CoenzymeQ10 taken once a day each morning by mouth.
Coenzyme Q10 : serum levels of greater or equal to 2.5 micrograms/mL.</description>
        </group>
        <group group_id="E2">
          <title>Prednisone Alone</title>
          <description>Prednisone taken once a day each morning by mouth
Prednisone : Prednisone 0/75 mg/kg/day.</description>
        </group>
        <group group_id="E3">
          <title>Coenzyme Q10 and Prednisone</title>
          <description>CoenzymeQ10 and prednisone each taken once a day in the morning by mouth.
Coenzyme Q10 : serum levels of greater or equal to 2.5 micrograms/mL.
Prednisone : Prednisone 0/75 mg/kg/day.</description>
        </group>
        <group group_id="E4">
          <title>Enhanced Standard of Care</title>
          <description>Enhanced standard of care.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Tonsilectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Limb edema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Virus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Mood alteration and agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper airway infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>In December 2007 the CINRG Data Safety and Monitoring Board (DSMB) met and recommended to close the study as the AAN had released practice parameters recommending that all patients with DMD should be offered treatment with corticosteroids.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Paula R. Clemens</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>412-648-9762</phone>
      <email>pclemens@pitt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

